Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorHenan Institute of Cardiovascular Epidemiology

About this trial

At present, there are 290 million cardiovascular patients in China, including 11 million patients with coronary heart disease. Remote ischemic preconditioning(RIPC) may play an effective endogenous cardiac protection.This study will explore whether long-term use of RIPC in patients with AMI after PCI and non interventional therapy can reduce the incidence of major adverse cardiovascular cerebrovascular events(MACCE) and improve clinical outcomes and long-term prognosis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with acute myocardial infarction were diagnosed in accordance with the criteria of the "Global Unified Definition of Fourth Myocardial Infarction"

Disqualifiers

The patients could not tolerate RIPC or RIPerC

Aortic dissection, coronary artery aneurysm, coronary artery fistula and other systemic organic diseases

The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively

severe liver dysfunction (bilirubin > 20 mmol / L, prothrombin time > 2.0 ratio)

Trial design

Design model

Parallel

Treatments tested in this trial

  • RIPerC

    Other intervention

    Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles

  • RIPC

    Other intervention

    Each 40 minutes treatment time, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle), a total of 4 cycles

Treatment groups

2,146 Participants
are divided into 3 treatment groups
Group A: Experimental Group1(RIPerC+RIPC)Experimental treatment 2 interventions
Group B: Experimental Group2(RIPerC)Experimental treatment 1 intervention
Group C: Control groupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Rate of MACCEs

MACCE(include Cardiovascular death, non-fatal acute myocardial infarction, revascularization, stroke, admission due to heart failure )

Time frame
12 months after discharge

Secondary outcomes

1

Rate of Cardiovascular death events

Rate of Cardiovascular death events

Time frame
12 months after discharge
2

Rate of non-fatal acute myocardial infarction events

Rate of non-fatal acute myocardial infarction events

Time frame
12 months after discharge
3

Rate of revascularization events

Rate of revascularization events

Time frame
12 months after discharge
4

Rate of stroke events

Rate of stroke events

Time frame
12 months after discharge

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.